Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-866-8548
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$129.16 million
Profitability
Miscellaneous
Employees179
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics Inc (NASDAQ:DNLI) issued its earnings results on Wednesday, November, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.08. The business earned $13.60 million during the quarter, compared to the consensus estimate of $10.86 million. Denali Therapeutics had a negative return on equity of 13.37% and a negative net margin of 44.73%. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
6 analysts have issued 1-year price objectives for Denali Therapeutics' stock. Their forecasts range from $19.00 to $35.00. On average, they expect Denali Therapeutics' stock price to reach $28.17 in the next year. This suggests a possible upside of 86.0% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.
What is the consensus analysts' recommendation for Denali Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.
What are Wall Street analysts saying about Denali Therapeutics stock?
Here are some recent quotes from research analysts about Denali Therapeutics stock:
- 1. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (11/7/2019)
- 2. HC Wainwright analysts commented, "We include in our valuation given their clinical stage, and view DNL310 as a free call option at this point. Our 12-month price target of $28/share is based on an equally weighted composite of (a) $29/share, as a 35x multiple of taxed and diluted FY34 GAAP EPS of $8.62 discounted back to and (b) an NPV of $28/ share (discount rate 12.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biopharmaceutial company." (8/8/2019)
Has Denali Therapeutics been receiving favorable news coverage?
Press coverage about DNLI stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Denali Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View News Stories for Denali Therapeutics.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include argenx (ARGX), China Biologic Products (CBPO), BioNTech (BNTX), Spark Therapeutics (ONCE), Repligen (RGEN), bluebird bio (BLUE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA) and Regenxbio (RGNX).
What other stocks do shareholders of Denali Therapeutics own?
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)
- Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)
- Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)
- Mr. Steve E. Krognes, CFO & Treasurer (Age 50)
- Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46)
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.
Who are Denali Therapeutics' major shareholders?
Denali Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.09%), Chicago Equity Partners LLC (0.08%), First Trust Advisors LP (0.08%), Russell Investments Group Ltd. (0.07%), Rhumbline Advisers (0.07%) and SG Americas Securities LLC (0.04%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.
Which major investors are selling Denali Therapeutics stock?
DNLI stock was sold by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC and Rhumbline Advisers. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics.
Which major investors are buying Denali Therapeutics stock?
DNLI stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, First Trust Advisors LP, Russell Investments Group Ltd., SG Americas Securities LLC, First Allied Advisory Services Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for Denali Therapeutics.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $15.14.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.45 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.View Additional Information About Denali Therapeutics.
What is Denali Therapeutics' official website?
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
